Cormorant Asset Management, LP Crinetics Pharmaceuticals, Inc. Transaction History
Cormorant Asset Management, LP
- $992 Million
- Q2 2025
A detailed history of Cormorant Asset Management, LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 400,000 shares of CRNX stock, worth $17.1 Million. This represents 1.16% of its overall portfolio holdings.
Number of Shares
400,000
Previous 600,000
33.33%
Holding current value
$17.1 Million
Previous $20.1 Million
42.83%
% of portfolio
1.16%
Previous 2.13%
Shares
7 transactions
Others Institutions Holding CRNX
# of Institutions
238Shares Held
90.3MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$397 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$274 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$267 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$249 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$240 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.3B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...